Other
Acquired IPRD
Bristol-Myers Squibb Acquired IPRD decreased by 93.3% to $94.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 50.0%, from $188.00M to $94.00M. Over 4 years (FY 2021 to FY 2025), Acquired IPRD shows an upward trend with a 33.9% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2021
Last reportedQ1 2026Apr 30, 2026
How to read this metric
High levels indicate an active M&A strategy to acquire new drug candidates, often leading to future growth but immediate accounting charges.
Detailed definition
Acquired In-Process Research and Development (IPRD) represents the value assigned to research projects obtained through...
Peer comparison
Common in large-cap pharma companies that rely on inorganic growth.
Metric ID:
other_acquired_iprdHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $793.00M | $271.00M | $89.00M | $333.00M | $400.00M | $30.00M | $52.00M | $75.00M | $158.00M | $80.00M | $600.00M | $12.95B | $132.00M | $262.00M | $30.00M | $188.00M | $1.51B | $633.00M | $1.39B | $94.00M |
| QoQ Change | — | -65.8% | -67.2% | +274.2% | +20.1% | -92.5% | +73.3% | +44.2% | +110.7% | -49.4% | +650.0% | >999% | -99.0% | +98.5% | -88.5% | +526.7% | +702.1% | -58.0% | +120.1% | -93.3% |
| YoY Change | — | — | — | — | -49.6% | -88.9% | -41.6% | -77.5% | -60.5% | +166.7% | >999% | >999% | -16.5% | +227.5% | -95.0% | -98.5% | >999% | +141.6% | >999% | -50.0% |
Range$30.00M – $12.95B
CAGR-36.2%
Avg YoY Growth>999%
Median YoY Growth-29.0%
Acquired IPRD at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's acquired iprd?
- Bristol-Myers Squibb (BMY) reported acquired iprd of $94.00M in Q1 2026.
- How has Bristol-Myers Squibb's acquired iprd changed year-over-year?
- Bristol-Myers Squibb's acquired iprd decreased by 50.0% year-over-year, from $188.00M to $94.00M.
- What is the long-term trend for Bristol-Myers Squibb's acquired iprd?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's acquired iprd has grown at a 33.9% compound annual growth rate (CAGR), from $1.16B to $3.72B.
- What does acquired iprd mean?
- Costs associated with purchasing ongoing research projects from other companies.